GILD vs MRNA: stock comparison and AI forecast
Gilead Sciences, Inc. (GILD) and Moderna, Inc. (MRNA) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
GILD Gilead Sciences, Inc.
- Market Cap
- $207.72B
- P/E Ratio
- –
- Size
- mega-cap
- AI Forecast
MRNA Moderna, Inc.
- Market Cap
- $88.16B
- P/E Ratio
- –
- Size
- large-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- GILD is 2.4 times larger than MRNA by market capitalization ($207.72B against $88.16B).
- GILD turns -12.5% of its revenue into net income, against -141.4% for MRNA.
- GILD carries 2.95 times debt per unit of equity, against 0.62 times for MRNA.
- GILD yields 1.97% in dividends; MRNA pays none.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | GILD | MRNA |
|---|---|---|
| Market Cap | $207.72B | $88.16B |
| P/B Ratio | 15.93x | 13.04x |
| Dividend Yield | 1.97% | – |
| EPS | $-3.15 | $-7.98 |
| Book Value/Share | $10.51 | $16.93 |
| Revenue/Share | $24.98 | $5.58 |
| FCF/Share | $11.11 | $-3.12 |
Profitability & Margins
| Metric | GILD | MRNA |
|---|---|---|
| ROE | -29.6% | -46.6% |
| ROA | -7.5% | -28.8% |
| ROIC | -6.0% | -39.4% |
| Gross Margin | 79.9% | 23.4% |
| Operating Margin | -7.6% | -149.0% |
| Net Margin | -12.5% | -141.4% |
| EBT Margin | -8.2% | -138.6% |
| Tax Rate | -52.5% | -2.1% |
Financial Health
| Metric | GILD | MRNA |
|---|---|---|
| Current Ratio | 1.38x | 2.29x |
| Quick Ratio | 1.22x | 2.18x |
| D/E Ratio | 2.95x | 0.62x |
| Financial Leverage | 3.94x | 1.62x |
| Interest Coverage | 1.9x | -85.7x |
| Working Capital | $4.55B | $3.28B |
Cash Flow
| Metric | GILD | MRNA |
|---|---|---|
| Operating Cash Flow | $14.48B | -$1.07B |
| Free Cash Flow | $13.78B | -$1.24B |
| Capital Spending | -$699M | -$171M |
| OCF Growth YoY | 49.8% | – |
| FCF Growth YoY | 50.4% | – |
| FCF/Sales | 44.5% | -55.8% |
| CapEx/Sales | 2.3% | 7.7% |
Operational Efficiency
| Metric | GILD | MRNA |
|---|---|---|
| Asset Turnover | 0.60x | 0.20x |
| Receivables Turnover | 6.2x | 131.1x |
| Inventory Turnover | 3.3x | 6.1x |
| Fixed Assets Turnover | 5.2x | 1.1x |
| Days Sales Outstanding | 59 days | 3 days |
| Days Inventory | 111 days | 60 days |
| Payables Period | 55 days | 36 days |
| Cash Conversion Cycle | 115 days | 27 days |
Income Statement
| Metric | GILD | MRNA |
|---|---|---|
| Total Revenue | $30.99B | $2.23B |
| Operating Income | -$2.36B | -$3.32B |
| Net Income | -$3.86B | -$3.15B |
| R&D Expense | $6.33B | $2.88B |
| SG&A Expense | $6.81B | – |
| Cost of Goods Sold | $6.22B | $1.71B |
Dividend & Shareholder Information
| Metric | GILD | MRNA |
|---|---|---|
| Dividends Per Share | $3.31 | – |
| Shares Outstanding | 1240M | 399M |
| Net Income Growth | -147.6% | – |
| EPS Growth | -148.8% | – |
GILD vs MRNA: stock comparison and AI forecast
Which is bigger, GILD or MRNA?
GILD is 2.4 times larger than MRNA by market capitalization ($207.72B against $88.16B).
Which one does Intratio's AI model rank higher, GILD or MRNA?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.